"We expect to begin recording product revenue from DARE to PLAY in the third quarter of 2026" (Chief Accounting Officer Haring-Layton), while adding, "Flora Sync LF5 consumer health product revenue is ...

Niagen Bioscience is back in focus after analysts trimmed their blended price target from US$14 to around US$12.60, signaling a more measured view of potential upside. Research notes describe this ...

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ ...

For generations, St. Louis has been known as a city of makers. Today, some of its most consequential builders work not with brick and steel, but with cells, code, crops, and data. This month, St.

ARK has been selling TWST for days.

Q1 2026 Management View “Overall, Q1 reflected continued progress on transforming Harvard Bioscience from a traditional tool provider into a leading supplier of the emerging translational science ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and ...

Daré Bioscience, Inc. ( DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT [Operator Instructions] We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets.

View Twist Bioscience Corp. TWST stock quote prices, financial information, real-time forecasts, and company news from CNN.

Margaret R. McLean delivered this address to the Keck Graduate Institute Convocation in September 2010. She is associate director of the Markkula Center for Applied Ethics and Director of Bioethics.